Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II nivolumab trial in class II-expressing microsatellite-stable colorectal cancer
ISRCTN40245896Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Aug 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in colorectal cancer (CRC), sponsored by University of Birmingham. Primary endpoint: Durable clinical benefit. Started Aug 2019; status: completed.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ISRCTN40245896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN40245896.